OM:SOBIBiotechs
Sobi (OM:SOBI) Stock May Be Fully Priced After A CTCL Licensing Deal
Swedish Orphan Biovitrum has delivered a strong share price run over the past five years. However, its current market multiples screen as overvalued, and broader valuation checks point to a stock that is not obviously cheap. For investors, that mix raises the question of how much of the company’s recent progress and pipeline activity is already reflected in today’s price.
Swedish Orphan Biovitrum has returned 155.5% over the past five years, which puts a clear spotlight on whether the...